VEGFA and renal cell carcinoma: In a retrospective analysis of 903 RCC patients randomized to sorafenib vs. placebo, baseline VEGF levels were associated with both PFS and OS in univariate analysis (PFS, P = 0.0013; OS, P = 0.0009) (49).